Please assess the completion status of the following clinical trial:

Trial Title: Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects of groups HibMenC and LicMenC at Visits 1, 2 and 3:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~* A male or female between and including 24 and 31 months of age at the time of Visit 1, between and including 40 and 43 months of age at Visit 2 and between and including 60 and 64 months at Visit 3.~* Written informed consent obtained from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Having completed the booster vaccination study 104056.~Subjects of group NoBoost at Visit 2 (UK only):~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~* A male or female between and including 40 and 43 months of age at Visit 2.~* Written informed consent obtained from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Having received a 3-dose primary vaccination with a MenC conjugate vaccine and a Hib containing vaccine before the age of 8 months.~Exclusion Criteria:~* Previous administration of booster dose of Hib or meningococcal serogroup C except booster study vaccines during the study 104056.~* History of H. influenzae type b or meningococcal diseases.~* For UK subjects of groups HibMenC and LicMenC only: previous administration of a booster dose of a pertussis-containing vaccine except booster study vaccines during the study 104056.

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 64 Months
- Healthy Volunteers: t

Study Arms:
- Menitorix Group (Type: EXPERIMENTAL): Previously primed in infancy with Menitorix™ and Infanrix-IPV™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
- Meningitec Group (Type: ACTIVE_COMPARATOR): Previously primed in infancy with Meningitec™ and Pediacel™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
- Meningitec+Hiberix Group (Type: ACTIVE_COMPARATOR): Previously primed (according to the routine UK immunisation schedule) with 3 doses of a Meningitec™ conjugate vaccine and a Hiberix™ containing vaccine before the age of 8 months without booster dose at 12 months of age (only for UK). All subjects received a booster dose of Infanrix-IPV™ and Menitorix™ at 40 to 43 months of age, intramuscularly in the deltoid region.~This group was added only at year 2 in UK (Meningitec+Hiberix Group) to comply with UK Hib Catch-up vaccination programme.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete